Claims

1. A compound of formula I



(I)

wherein

each of $R^0$, $R^1$, $R^2$,and $R^3$ independently is hydrogen, $C_1$-$C_8$alkyl, $C_2$-$C_8$alkenyl, $C_2$-$C_8$alkinyl, $C_3$-$C_8$cycloalkyl, $C_3$-$C_8$cycloalkyl$C_1$-$C_8$alkyl, $C_5$-$C_{10}$aryl$C_1$-$C_8$alkyl, hydroxy$C_1$-$C_8$alkyl, $C_1$-$C_8$alkoxy$C_1$-$C_8$alkyl, amino$C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, unsubstituted or substituted $C_5$-$C_{10}$aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, $C_1$-$C_8$alkoxy, hydroxy$C_1$-$C_8$alkoxy, $C_1$-$C_8$alkoxy$C_1$-$C_8$alkoxy, halo$C_1$-$C_8$alkoxy, unsubstituted or substituted $C_5$-$C_{10}$aryl$C_1$-$C_8$alkoxy, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted heterocyclyl$C_1$-$C_8$alkoxy, unsubstitued or substituted amino, $C_1$-$C_8$alkylthio, $C_1$-$C_8$alkylsulfinyl, $C_1$-$C_8$alkylsulfonyl, $C_5$-$C_{10}$arylsulfonyl, halogen, carboxy, $C_1$-$C_8$alkoxycarbonyl, unsubstitued or substituted carbamoyl, unsubstitued or substituted sulfamoyl, cyano or nitro; or

$R^0$ and $R^1$, $R^1$ and $R^2$, and/or $R^2$ and $R^3$ form, together with the carbon atoms to which they are attached, a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S;

$R^4$ is hydrogen or $C_1$-$C_8$alkyl;

each of $R^5$ and $R^6$ independently is hydrogen, $C_1$-$C_8$alkyl, $C_1$-$C_8$alkoxy$C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, $C_1$-$C_8$alkoxy, halogen, carboxy, $C_1$-$C_8$alkoxycarbonyl, unsubstitued or substituted carbamoyl, cyano, or nitro; and

each of $R^7$, $R^8$, $R^9$, and $R^{10}$ independently is $C_1$-$C_8$alkyl, $C_2$-$C_8$alkenyl, $C_2$-$C_8$alkinyl, $C_3$-$C_8$cycloalkyl, $C_3$-$C_8$cycloalkyl$C_1$-$C_8$alkyl, $C_5$-$C_{10}$aryl$C_1$-$C_8$alkyl, hydroxy$C_1$-$C_8$alkyl, $C_1$-$C_8$alkoxy$C_1$-$C_8$alkyl, amino$C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, unsubstituted or substituted $C_5$-$C_{10}$aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, $C_1$-$C_8$alkoxy, hydroxy$C_1$-$C_8$alkoxy, $C_1$-$C_8$alkoxy$C_1$-$C_8$alkoxy, halo$C_1$-$C_8$alkoxy, unsubstituted or substituted $C_5$-$C_{10}$aryl$C_1$-$C_8$alkoxy, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted heterocyclyl$C_1$-

$C_8$alkoxy, unsubstitued or substituted amino, $C_1$-$C_8$alkylthio, $C_1$-$C_8$alkylsulfinyl, $C_1$-$C_8$alkylsulfonyl, $C_5$-$C_{10}$arylsulfonyl, halogen, carboxy, $C_1$-$C_8$alkoxycarbonyl, unsubstitued or substituted carbamoyl, unsubstitued or substituted sulfamoyl, cyano or nitro; wherein $R^7$, $R^8$ and $R^9$ independently of each other can also be hydrogen;

or $R^7$ and $R^8$, $R^8$ and $R^9$, and/or $R^9$ and $R^{10}$ form together with the carbon atoms to which they are attached, a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S;

A is C or N;

and salts thereof.

2. A compound of formula I according to claim 1, wherein

each of $R^0$ or $R^2$ independently is hydrogen, $C_1$-$C_8$alkyl, hydroxy$C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, unsubstituted or substituted $C_5$-$C_{10}$aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, $C_1$-$C_8$alkoxy, halo$C_1$-$C_8$alkoxy, $C_5$-$C_{10}$aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyl$C_1$-$C_8$alkoxy, unsubstituted or substituted amino, $C_1$-$C_8$alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl;

$R^1$ is hydrogen, $C_1$-$C_8$alkyl, hydroxy$C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, unsubstituted or substituted $C_5$-$C_{10}$aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, $C_1$-$C_8$alkoxy, halo$C_1$-$C_8$alkoxy, $C_5$-$C_{10}$aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyl$C_1$-$C_8$alkoxy, unsubstituted or substituted amino, $C_1$-$C_8$alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl;

$R^3$ is hydrogen, $C_1$-$C_8$alkyl, hydroxy$C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S, $C_1$-$C_8$alkoxy, substituted amino, $C_1$-$C_8$alkylsulfonyl, $C_5$-$C_{10}$arylsulfonyl, halogen, carboxy, substituted or unsubstituted carbamoyl, unsubstituted or substituted sulfamoyl; or

each pair of adjacent substituents $R^0$ and $R^1$, or $R^1$ and $R^2$, or $R^2$ and $R^3$ is $-CH_2-NH-CO-$, $-CH_2-CH_2-NH-CO-$, $-CH_2-CO-NH-$, $-CH_2-CH_2-CO-NH-$, $-CH_2-NH-SO_2-$, $-CH_2-CH_2-NH-SO_2-$, $-CH_2-SO_2-NH-$, $-CH_2-CH_2-SO_2-NH-$, $-CH_2-CH_2-SO_2-$, $-CH_2-CH_2-CH_2-SO_2-$, $-O-CH_2-O-$, or $-O-CF_2-O-$, and such pairs wherein hydrogen in NH is replaced by $C_1$-$C_8$alkyl;

$R^4$ is hydrogen or $C_1$-$C_8$alkyl;

$R^5$ is hydrogen; $C_1$-$C_8$alkyl, halogen, halo$C_1$-$C_8$alkyl, cyano or nitro;

$R^6$ is hydrogen;

each of $R^7$ and $R^9$ independently is hydrogen, $C_1$-$C_8$alkyl, hydroxy$C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, unsubstituted or substituted $C_5$-$C_{10}$aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, $C_1$-$C_8$alkoxy, halo$C_1$-$C_8$alkoxy, $C_5$-$C_{10}$aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyl$C_1$-$C_8$alkoxy, unsubstituted or substituted amino, $C_1$-$C_8$alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl;

$R^8$ is hydrogen, $C_1$-$C_8$alkyl, hydroxy$C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, $C_5$-$C_{10}$aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, $C_1$-$C_8$alkoxy, halo$C_1$-$C_8$alkoxy, $C_5$-$C_{10}$aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyl$C_1$-$C_8$alkoxy, unsubstituted or substituted amino, $C_1$-$C_8$alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano, or nitro; and

$R^{10}$ is $C_1$-$C_8$alkyl, hydroxy$C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, $C_1$-$C_8$alkoxy, unsubstituted or substituted heterocyclyl$C_1$-$C_8$alkoxy, unsubstituted or substituted amino, halogen, carboxy, carbamoyl, or unsubstituted or substituted sulfamoyl; or

each pair of adjacent substituents $R^7$ and $R^8$, or $R^8$ and $R^9$ or $R^9$ and $R^{10}$, is –NH-CH=CH-, -CH=CH-NH-, –NH-N=CH-, –CH=N-NH-, -$CH_2$-$CH_2$-$CH_2$-, -$CH_2$-$CH_2$-$CH_2$-$CH_2$-, -$CH_2$-$CH_2$-O-, -CH=CH-O-, -O-$CH_2$-O-, or -O-$CF_2$-O-;

A is C or N.

3. A compound of formula I according to claim 1, wherein

each of $R^0$ or $R^2$ independently is hydrogen, $C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, $C_1$-$C_8$alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyl$C_1$-$C_8$alkoxy, unsubstituted or substituted amino, or halogen;

$R^1$ is hydrogen, $C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, $C_1$-$C_8$alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyl$C_1$-$C_8$alkoxy, unsubstituted or substituted amino, halogen;

$R^3$ is hydrogen, $C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S, $C_1$-$C_8$alkoxy,

substituted amino, $C_1$-$C_8$alkylsulfonyl, $C_5$-$C_{10}$arylsulfonyl, halogen, carboxy, substituted or unsubstituted carbamoyl, or unsubstituted or substituted sulfamoyl; or

each pair of adjacent substituents $R^0$ and $R^1$, or $R^1$ and $R^2$, or $R^2$ and $R^3$ is $-CH_2-NH-CO-$, $-CH_2-NH-SO_2-$, $-CH_2-CH_2-SO_2-$, $-O-CH_2-O-$, or $-O-CF_2-O-$, and such pairs wherein hydrogen in NH is replaced by $C_1$-$C_8$alkyl;

$R^4$ is hydrogen;

$R^5$ is hydrogen, halogen, halo$C_1$-$C_8$alkyl, or nitro;

$R^6$ is hydrogen;

each of $R^7$ and $R^9$ independently is hydrogen, $C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, unsubstituted or substituted $C_5$-$C_{10}$aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, $C_1$-$C_8$alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyl$C_1$-$C_8$alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;

$R^8$ is hydrogen, $C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, $C_5$-$C_{10}$aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, $C_1$-$C_8$alkoxy, halo$C_1$-$C_8$alkoxy, $C_5$-$C_{10}$aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyl$C_1$-$C_8$alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted sulfamoyl, or nitro; and

$R^{10}$ is $C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, $C_1$-$C_8$alkoxy, unsubstituted or substituted heterocyclyl$C_1$-$C_8$alkoxy, unsubstituted or substituted amino, or halogen; or

each pair of adjacent substituents $R^7$ and $R^8$, or $R^8$ and $R^9$ or $R^9$ and $R^{10}$, is –NH-CH=CH-, -CH=CH-NH-, –NH-N=CH-, –CH=N-NH-, $-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-CH_2-$, $-O-CH_2-O-$, or $-O-CF_2-O-$;

A is C or N.

4. A compound of formula I according to claim 1, wherein

each of $R^0$ or $R^2$ independently is hydrogen, piperazino, N-methylpiperazino or 1-methyl-4-piperidyloxy;

$R^1$ is hydrogen, piperazino, N-methylpiperazino, morpholino, 1-methyl-4-piperidinyloxy, 3-morpholinopropoxy or 2-morpholinoethoxy;

$R^3$ is sulfamoyl, methylsulfamoyl or propylsulfamoyl; or

the pair of adjacent substituents $R^0$ and $R^1$, or $R^1$ and $R^2$ is $-O-CH_2-O-$, or the pair of adjacent substituents $R^2$ and $R^3$ is $-CH_2-NH-CO-$ or $-CH_2-NH-SO_2-$;

$R^4$ is hydrogen;

$R^5$ is hydrogen, chloro, bromo, trifluoromethyl or nitro;

$R^6$ is hydrogen;

each of $R^7$ and $R^9$ independently is hydrogen, $C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, unsubstituted or substituted $C_5$-$C_{10}$aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, $C_1$-$C_8$alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyl$C_1$-$C_8$alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;

$R^8$ is hydrogen, $C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, $C_5$-$C_{10}$aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, $C_1$-$C_8$alkoxy, halo$C_1$-$C_8$alkoxy, $C_5$-$C_{10}$aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyl$C_1$-$C_8$alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted sulfamoyl, or nitro; and

$R^{10}$ is $C_1$-$C_8$alkyl, halo$C_1$-$C_8$alkyl, $C_1$-$C_8$alkoxy, unsubstituted or substituted heterocyclyl$C_1$-$C_8$alkoxy, unsubstituted or substituted amino, or halogen; or

each pair of adjacent substituents $R^7$ and $R^8$, or $R^8$ and $R^9$ or $R^9$ and $R^{10}$, is –NH-CH=CH-, -CH=CH-NH-, –NH-N=CH-, –CH=N-NH-, -$CH_2$-$CH_2$-$CH_2$-, -$CH_2$-$CH_2$-$CH_2$-$CH_2$-, -O-$CH_2$-O-, or -O-$CF_2$-O-;

A is C or N.

5. A compound of formula I according to claim 1, wherein

each of $R^0$ or $R^2$ independently is hydrogen, piperazino, N-methylpiperazino or 1-methyl-4-piperidyloxy;

$R^1$ is hydrogen, piperazino, N-methylpiperazino, morpholino, 1-methyl-4-piperidinyloxy, 3-morpholinopropoxy or 2-morpholinoethoxy;

$R^3$ is sulfamoyl, methylsulfamoyl or propylsulfamoyl; or

the pair of adjacent substituents $R^0$ and $R^1$, or $R^1$ and $R^2$ is -O-$CH_2$-O-, or the pair of adjacent substituents $R^2$ and $R^3$ is -$CH_2$-NH-CO- or -$CH_2$-NH-$SO_2$-;

$R^4$ is hydrogen;

$R^5$ is hydrogen, chloro, bromo, trifluoromethyl or nitro;

$R^6$ is hydrogen;

each of $R^7$ and $R^9$ independently is hydrogen, methyl, isopropyl, trifluoromethyl, phenyl, o-, m- or p-methoxyphenyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy,

ethoxy, isopropoxy, phenoxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 2-(1-imidazolyl)ethoxy, dimethylamino, fluoro, morpholinocarbonyl, piperidinocarbonyl, piperazinocarbonyl or cyclohexylcarbamoyl;

$R^8$ is hydrogen, methyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, trifluoromethoxy, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 3-(N-methylpiperazino)-propoxy, methylamino, fluoro, chloro, sulfamoyl or nitro; and

$R^{10}$ is methyl, butyl, methoxy, ethoxy, 2-(1-imidazolyl)ethoxy, methylamino, dimethylamino or fluoro; or

the pair of adjacent substituents $R^7$ and $R^8$ or $R^8$ and $R^9$ is $-O-CH_2-O-$ or the pair of adjacent substituents $R^9$ and $R^{10}$ is -NH-CH=CH-, -CH=N-NH-, $-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-CH_2-$ or $-O-CF_2-O-$;

A is C or N.

6. A compound of formula I according to claim 1, wherein

each of $R^0$, $R^1$ or $R^2$ is hydrogen;

$R^3$ is sulfamoyl, methylsulfamoyl or propylsulfamoyl;

$R^4$ is hydrogen;

$R^5$ is chloro or bromo;

$R^6$ is hydrogen;

each of $R^7$ and $R^9$ independently is hydrogen, methyl, isopropyl, trifluoromethyl, phenyl, o-, m- or p-methoxyphenyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, isopropoxy, phenoxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 2-(1-imidazolyl)ethoxy, dimethylamino, fluoro, morpholinocarbonyl, piperidinocarbonyl, piperazinocarbonyl or cyclohexylcarbamoyl;

$R^8$ is hydrogen, methyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, trifluoromethoxy, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 3-(N-methylpiperazino)-propoxy, methylamino, fluoro, chloro, sulfamoyl or nitro; and

$R^{10}$ is methyl, butyl, methoxy, ethoxy, 2-(1-imidazolyl)ethoxy, methylamino, dimethylamino or fluoro; or

the pair of adjacent substituents $R^7$ and $R^8$ or $R^8$ and $R^9$ is $-O-CH_2-O-$, or the pair of adjacent substituents $R^9$ and $R^{10}$ is -NH-CH=CH-, -CH=N-NH-, $-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-CH_2-$ or $-O-CF_2-O-$;

A is C or N.

7. The compound of formula I according to claim 1, wherein each of $R^0$, $R^1$ or $R^2$ is hydrogen, $R^3$ is methylsulfamoyl, $R^4$ is hydrogen, $R^5$ is bromo, $R^6$ is hydrogen, each of $R^7$ and $R^8$ is methoxy, $R^9$ is hydrogen, and $R^{10}$ is methyl, and A is C or N.

8. The compound of formula I according to claim 1, wherein each of $R^0$, $R^1$ or $R^2$ is hydrogen, $R^3$ is methylsulfamoyl, $R^4$ is hydrogen, $R^5$ is bromo, $R^6$ is hydrogen, each of $R^7$ and $R^8$ is hydrogen, and the pair of adjacent substituents $R^9$ and $R^{10}$ is $-CH_2-CH_2-CH_2-$, and A is C or N.

9. The compound of formula 2-{5-Chloro-2-[4-(3-methylamino-pyrrolidin-1-yl)-phenylamino]-pyrimidin-4-ylamino}-N-isopropyl-benzenesulfonamide.

10. A process for the production of a compound of formula I according to claim 1, comprising reacting a compound of formula II



(II)

wherein $R^0$, $R^1$, $R^2$, $R^3$, $R^4$, $R^5$, and $R^6$ are as defined in claim 1, and Y is a leaving group, with a compound of formula III



(III)

wherein $R^7$, $R^8$, $R^9$ and $R^{10}$ are as defined in claim 1;

and, if desired, converting a compound of formula I, wherein the substituents have the meaning as defined in claim 1, into another compound of formula I as defined in claim 1;

and recovering the resulting compound of formula I in free from or as a salt, and, when required, converting the compound of formula I obtained in free form into the desired salt, or an obtained salt into the free form.

11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 9, as active ingredient together with one or more pharmaceutically acceptable diluents or carriers.

12. The use of a compound according to any one of claims 1 to 9 for the manufacture of a medicament for the treatment or prevention of neoplastic diseases and immune system disorders.

13. A combination comprising a therapeutically effective amount a compound according to any one of claims 1 to 9 and one or more further drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders.

14. A method for the treatment of neoplastic diseases and immune system disorders in a subject in need thereof which comprises administering an effective amount of a compound according to any one of claims 1 to 9 or a pharmaceutical composition comprising same.

15. Use of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of a disease which responds to inhibition of focal adhesion kinase or/and IGF-1 Receptor.

16. The use according to claim 15, wherein the disease to be treated is selected from proliferative disease .

17. The use according to claim 16, wherein the proliferative disease to be treated is selected from a tumor of, breast, renal , prostate, colorectal, thyroid, ovarian, pancreas, neuronal, lung, uterine and gastro-intestinal tumours as well as osteosarcomas and melanomas.

18. The use according to claim 15, wherein the disease to be treated is an immune disease.

19. Use of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of inflammatory and/or an immune disorder.

20. Use according to claim 19 wherein the inflammatory and/or immune disorder is selected from transplant rejection, allergy and autoimmune disorders mediated by immune cells including T lymphocytes, B lymphocytes, macrophages, dendritic cells, mast cells and eosinophils.

21. The use according to any one of claims 14 to 19, wherein the compound is 2-[5-Bromo-2-(2-methoxy-5-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide or a pharmaceutically acceptable salt thereof.

22. The use according to any one of claims 14 to 19, wherein the compound is selected from 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide, $N^2$-(4-[1,4']Bipiperidinyl-1'-yl-2-methoxy-phenyl)-5-chloro-$N^4$-[2-(propane-1-sulfonyl)-phenyl]-pyrimidine-2,4-diamine and 2-{5-Chloro-2-[2-methoxy-4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-ylamino}-N-isopropyl-benzenesulfonamide, or a pharmaceutically acceptable salt thereof.